Leadman (300289.SZ) announced its first-half results, with a net loss of 7.113 million yuan to mother

According to the Zhitong Finance App, Leadman (300289.SZ) released the 2026 semi-annual report. During the reporting period, the company achieved revenue of 152 million yuan, a year-on-year decrease of 5.31%. The net loss attributable to shareholders of the listed company was $7.113 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was $105.352 million.

The in vitro diagnostic reagent business was the company's main source of revenue, achieving revenue of 110.7013 million yuan, up 1.69% year on year, accounting for 72.85% of revenue; diagnostic instruments (including accessories and consumables) business realized revenue of 17.2313 million yuan, down 24.23% year on year, accounting for 11.34% of revenue; biochemical raw materials business achieved revenue of 6.891,000 yuan, down 11.32% year on year, accounting for 4.48% of revenue; other businesses (mainly housing rental and property management) achieved revenue 17.226 million yuan, a year-on-year decrease of 18.75%, accounting for 11.33% of revenue.